About
Zealar Inc. is committed to improve the quality of life by developing cutting-edge technologies and platforms enabling early disease diagnosis and personalized medicine discovery and by creating artificial intelligence for optimal medical services.
Enabling Technologies for Biomedical Research (ETBR)
ETBR invents and develops technologies and associated instruments that will enable biomedical researchers to detect and identify molecules that cannot be analyzed economically. Specifically, ETBR will develop Nano Open Tubular Liquid Chromatography (NOTLC) for high-speed, high-throughput, and high-accuracy proteomic and single cell analyses.
​
In the past two decades, Professor Liu has invented various new biotech tools, and NOTLC is identified as the most promising one for commercialization. The basic research has been done. ETBE will focus on producing robust and reliable instruments, developing analytical methods and building intellectual properties for its products.
AIM is Zealar's strategic investment and a developing business that has the greatest potential to grow. AI is like the internet in the early 1990s and anticipated to be a multi trillion-dollar industry. Zealar can't afford to let this opportunity pass by. Initially, Zealar will concentrate its effort on intensive home-care suites for elderly patients and AI platforms to facilitate and enhance the implementation of the home-care suites.
